AliveandKick'n the podcast
I sit down with Richard Wu, Lynch Syndrome patient and runner in the TCS New York City Marathon. Richard didn't know about his Lynch Syndrome but was experiencing unexplained fevers, especially on trips. At 38, he was surprised to hear of his colon cancer. The immunotherapy not only cured his cancer without surgery, but seemingly the fevers have ended as well. Richard is on baby aspirin moving forward and so far so good. We look forward to cheering Richard at the NYC Marathon this weekend and a link to his page will be attached....
info_outlineAliveandKick'n the podcast
I sit down with Dr Yvonne Bombard, scientist focusing on improving access to genetic testing for personalized medicine, at Unity Health in Toronto, as well as being founder and CEO of The Genetics Advisor. Dr Bombard is a problem solver at heart, always looking for ways to clear access for others. Genetics Advisor, which has been around for many years, is meant to augment and/or support genetic counseling. People using the tool have significantly high levels of knowledge, even compared with clinician driven sessions. Studies also show it saves provider consult time by...
info_outlineAliveandKick'n the podcast
I sit down with Dr Magali Svrcek, Professor of Pathology at the University of Sorbonne in Paris, and she discusses her role as a GI Pathologist. Dr Svrcek discusses Microsatellite Instability, digital tools and Immunohistochemistry. Dr Svrcek wrote her script in English, so I in turn wrote my introduction and closing en Francais. I hope my French is ok. With fewer Pathologists, especially internationally, digital pathology could be a solution. In working with Owkin, the collaboration, MsIntuit, an AI diagnostic tool to detect MSI, and is the first to be CE...
info_outlineAliveandKick'n the podcast
I sit down with Dr Luis Diaz Jr, physican scientist at Memorial Sloan Kettering, and we share some history of mismatch repair, lynch syndrome and the evolution. Of course we talked about the primary rectal cancer study where they showed immunotherapy was curative for MMR/MSI High tumors. A second study for multiple cancer locations had 85% response rate and 40% had no side effects. Shout out of course to Dr Zsofia Stadler, my oncologist, working on another study of patients treated with immunotherapy, and if further cancers can be prevented. The future may be the Lynch...
info_outlineAliveandKick'n the podcast
I sit down with Dr Aparajita Singh, Gastroenterologist and Director of the Lynch Syndrome Center at UCSF, where it truly is a team effort taking care of Lynch Syndrome patients. Aside from me mispronouncing Lynch Syndrome, it was a wonderful engaging conversation. UCSF Lynch Syndrome Center should have the links to everything discussed, which was a lot. Check it out.
info_outlineAliveandKick'n the podcast
I sit down with Dr Timothy Yen, Gastroenterologist and Clinical Informaticist at Loma Linda University. Dr Yen was building the Lynch Syndrome program at Loma Linda when he discovered Epic Cosmos, where the Epic's Care Everywhere could be used for research, regardless of the health system. Epic Cosmos unlike other modules, isn't built around claims data. Now Dr Yen can pull de-identified data from thousands of patients, aggregate statistics and more. Cosmos is free for a health system to join, but they just need Care Everywhere. It also has a system to...
info_outlineAliveandKick'n the podcast
I sit down with Marina Udier, CEO of Nouscom, a Swiss company working on the Lynch Syndrome vaccine. Nous209 is designed to intercept tumors in Lynch Syndrome cancers. The 209 comes from the frameshifts of neoantigens, whether sporadic or hereditary. Idea is to educate the T-cells before cancers start forming. The data at AACR presented was very promising. They are also running a study on metastatic colorectal cancer patients, mostly without Lynch Syndrome, but MSI high. So how many people are tested positive for Lynch Syndrome each year? Next steps...
info_outlineAliveandKick'n the podcast
I sit down with Dr Aasma Shaukat, Gastroenterologist and Professor of Population Health, who is also trained in Epidemiology and Clinical Research, and Director of GI Outcomes Research at NYU Langone Health, Grossman School of Medicine. We talk about progress in healthcare fields including gastroenterology. We talk microbiome (I compared my digestive tract to the ocean). We did talk colonoscopy prep in quite a bit of detail. We also talk about screening rates in the NYC area< C5 and how fortunate we are to work and live in an area that really tries to be inclusive...
info_outlineAliveandKick'n the podcast
I sit down with Dr. Matthias Kloor, Acting Medical Director Applied Tumor Biology at Heidelberg University. We discuss the thought process followed by the hurdles faced in trying to get a Lynch Syndrome vaccine, through the phases, to potentially the proverbial bedside. We discussed collaboration with the NCI in bringing this and other projects to market. We also talk about the European Hereditary Tumor Group, whose conference this year is also in Heidelberg. EHTG is a great group, one that has embraced the advocacy community, similar to CGAIGC and InSIGHT.
info_outlineAliveandKick'n the podcast
I sit down with Sandra and Javier Corrales, who share their Lynch Syndrome story. Javier has been open with his diagnosis so his family can be proactive in their care. Sandra, who has a history of cancer in her family as well, has been the teammate in this process every step of the way. With the Lynch Syndrome diagnosis, they now see a path forward. They share how they deal with family, including the kids, and having age-appropriate conversations. Besides participating in AliveAndKickn's Living with Lynch annual program, they coordinated a community...
info_outlineI sit down with Dr. Patrick Soon-Shiong, Executive Chairman and Global Chief Medical and Scientific Officer for Immunity Bio, and we talk everything cancer vaccines scientifically, including the potential Lynch Syndrome vaccine. A new term is announced on our podcast, Tumor Educated Lymphocytes. Dr Soon-Shiong, succinctly summarized a very complicated vaccine space, which will be important as more patients enroll in trials and learn about their genetics.